Modern approaches to the choice of hypoglycemic therapy in patients with type 2 diabetes mellitus: a niche of DPP-4 inhibitors


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Among 9 classes of antidiabetic drugs used, dipeptidyl peptidase-4 (IDPP-4) inhibitors were firmly established in medical practice about 14 years ago. To date, drugs of this group are confidently prescribed as the first-line therapy for type 2 diabetes mellitus. Features of drugs of this class allow the use of DPP-4 inhibitors in various groups of patients, especially requiring close attention. These include the older age group, patients prone to hypoglycemia, and suffering from end-stage renal disease, when the possibilities for choosing hypo-glicemic therapy are extremely limited. Furthermore, the safety of the use of most drugs of this group in the presence of cardiovascular pathology is also important, and it allows them to be used in the vast majority of patients with type 2 diabetes mellitus.

Full Text

Restricted Access

About the authors

N. A Chernikova

Russian Medical Academy of Continuous Professional Education

Email: nachendoc@yandex.ru
Dr. Sci. (Med.), Associate Professor, Department of Endocrinology

O. A Knyshenko

Russian Medical Academy of Continuous Professional Education

References

  1. IDF Diabetes Atlas - 7th edition. [Cited 2016 Nov 12]. Available from: http://www.diabetesatlas.org
  2. ВОЗ. URL: https://www.who.int/features/ factfiles/diabetes/ru
  3. American Diabetes Association. Approaches to glycemic treatment. Diab Care. 2016;39(Suppl. 1):S52-9.
  4. URL: https://www.rlsnet.ru/tn_indexjd_37571. htm
  5. Holst J.J., Knop F.K., Vilsb0ll T., et al. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diab Care. 2011;34(Suppl. 2):S251-57.
  6. Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-37. doi: 10.1016/j.cmet.2013.04.008.
  7. Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs. 2013;18(2):245-58.
  8. Nauck M.A. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(1 Suppl.):S3-18. Doi: 10.1016/j. amjmed.2010.11.002.
  9. Zhong J, Rao X., Rajagopalan S. An emerging role of dipeptidylpeptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atheroscler. 2013;226(2):305-14. doi: 10.1016/j.atherosclerosis.2012.09.012.
  10. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26. Doi: http://dx.doi. org/10.1056/NEJMoa1307684
  11. White W.B., Cannon C.P, Heller S.R., et al.; for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-35. doi: 10.1056/NEJMoa1305889.
  12. Green J.B., Bethel M.A., Armstrong PW., et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-42. Doi: 10.1056/ NEJMoa1501352.
  13. Savarese G., Perrone-Filardi P, DAmore C., et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis. Int J Cardiol. 2015;181:239-44. Doi: http://dx.doi. org/10.1016/j.ijcard.2014.12.017.
  14. Scirica B.M., Braunwald E., Raz I., et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI53 randomized trial. Circulation. 2014;130:1579-88. doi: 10.1161/CIRCULATI0NAHA.115.015511.
  15. Мкртумян А.М., Бирюкова Е.В., Морозова И.А. Эффективность и безопасность ситаглиптина: доказательная база для клинического применения и перспективы. Поликлиника. 2015;1-2:63-70.
  16. Ma M., Hasegawa Y, Koibuchi N., et al. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. Cardiovasc Diabetol. 2015;14:54.
  17. Zannad F, Cannon C.P, Cushman W.C., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, doubleblind trial. Lancet. 2015;385:2067-76. doi: 10.1016/s0140-6736(14)62225-x.
  18. Toh S., Hampp C., Reichman M.E., et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other anti-hyperglycemic drugs: a retrospective cohort study. Ann Intern Med. 2016;164(11):705-14. Doi: 10.732 6/M15-2568.
  19. Hippisley-Cox J., Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ. 2016;12(354):i3477. Doi: https://doi. org/10.1136/bmj.i3477.
  20. Filion K.B., Azoulay L., Platt R.W., et al., CNODES Investigators. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374(12):1145-54. Doi: 10.1056/ NEJMoa1506115.
  21. Schernthaner G, Cahn A, Raz I. Is the use of DPP-4 inhibitors associated with an increased risk for heart failure? lessons from EXAMINE, SAVOR and TECOS. Diab Care. 2016;39(Suppl. 2):S210-18. Doi: https://doi.org/10.2337/dcS15-3009.
  22. Cooper M.E., Perkovic V, McGill J.B., et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis. 2015;66(3):441-49. Doi: 10.1053/j. ajkd.2015.03.024.
  23. Mosenzon O, leibowitz G, Bhatt D.L., et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diab. Care. Oct 17 pii: dc160621. [Epub ahead of print].
  24. Roussel R, et al. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. Diab Obes Metab. 2019;21:781-90. doi: 10.1111/dom.13574.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies